Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database.

Curr Drug Targets

Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL33612, USA.

Published: August 2024

Drug repurposing is an emerging approach to reassigning existing pre-approved therapies for new indications. The FDA Adverse Event Reporting System (FAERS) is a large database of over 28 million adverse event reports submitted by medical providers, patients, and drug manufacturers and provides extensive drug safety signal data. In this review, four common drug repurposing strategies using FAERS are described, including inverse signal detection for a single disease, drug-drug interactions that mitigate a target ADE, identifying drug-ADE pairs with opposing gene perturbation signatures and identifying drug-drug pairs with congruent gene perturbation signatures. The purpose of this review is to provide an overview of these different approaches using existing successful applications in the literature. With the fast expansion of adverse drug event reports, FAERS-based drug repurposing represents a promising strategy for discovering new uses for existing therapies.

Download full-text PDF

Source
http://dx.doi.org/10.2174/0113894501290296240327081624DOI Listing

Publication Analysis

Top Keywords

drug repurposing
16
adverse event
12
fda adverse
8
event reporting
8
reporting system
8
system faers
8
event reports
8
gene perturbation
8
perturbation signatures
8
drug
7

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!